Covalon Technologies Ltd. selected as one of 50 top performers listed on the TSX Venture
June 26, 2007
Mississauga, Ontario – June 26, 2007: Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSX Venture: COV) announced that it has been selected as one of the top 50 companies on the TSX Venture exchange and was ranked 7 of the top 10 companies in the Life Sciences market sector.
Dr. Frank DiCosmo, President and CEO said: “I am delighted that Covalon is among a select group of companies recognized as the “2007 TSX Venture 50” of over 2,100 companies (The Globe and Mail, Wednesday, June 20, 2007, Report on the TSX Venture 50, page B9). The TSX Venture has provided embryonic companies like Covalon a strong venue for building shareholder value and being recognized as one of the 2007 TSX Venture 50 is a direct result of a strong and dedicated effort of a talented group of scientists and researchers, administrative staff, managers and Directors. We are excited to sustain our efforts into the future as we innovate on current and new platforms of technology that keeps us in the lead of the marketplace.”
Brad Williams, Chairman of the Board commented: “We are pleased in being recognized as the Best of the Best and attribute this accomplishment to our dedicated team of employees, and the shareholders who have made Covalon the success it is today. We remain focused on delivering the innovations that will allow our Company to remain at the top of our field in the quarters and years that are ahead of us.”
Covalon Technologies Ltd. is a company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility, and microbial attachment.
For further information please contact: William Jackson, CFO & COO
Covalon Technologies Ltd.
T: (905) 568-8400
F: (905) 568-5200
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has neither approved nor disapproved of the contents of this release.
This document contains forward-looking statements. These statements relate to future events or future performance. In some cases, forward-looking statements can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of any of these terms or comparable terminology. Such statements reflect the current views of management of the Company with respect to future events. Actual events or results may differ materially. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
 |